Human Investing LLC Lowers Stock Position in Eli Lilly and Company (NYSE:LLY)

Human Investing LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,688 shares of the company’s stock after selling 74 shares during the period. Eli Lilly and Company accounts for about 0.4% of Human Investing LLC’s holdings, making the stock its 29th biggest position. Human Investing LLC’s holdings in Eli Lilly and Company were worth $2,381,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock worth $7,699,000 after purchasing an additional 1,620 shares during the period. Flynn Zito Capital Management LLC acquired a new stake in Eli Lilly and Company in the first quarter valued at $263,000. Wambolt & Associates LLC lifted its holdings in Eli Lilly and Company by 33.1% in the first quarter. Wambolt & Associates LLC now owns 1,807 shares of the company’s stock valued at $1,374,000 after acquiring an additional 449 shares during the period. ORBA Wealth Advisors L.L.C. lifted its holdings in Eli Lilly and Company by 4.1% in the first quarter. ORBA Wealth Advisors L.L.C. now owns 385 shares of the company’s stock valued at $300,000 after acquiring an additional 15 shares during the period. Finally, DORCHESTER WEALTH MANAGEMENT Co acquired a new stake in Eli Lilly and Company in the first quarter valued at $229,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LLY has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $1,025.00 price target on shares of Eli Lilly and Company in a research report on Thursday, October 3rd. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Barclays dropped their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Finally, Berenberg Bank lifted their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,009.00.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $818.93 on Friday. The stock’s 50 day moving average price is $911.04 and its 200 day moving average price is $865.33. The firm has a market capitalization of $778.34 billion, a PE ratio of 88.53, a price-to-earnings-growth ratio of 3.07 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a one year low of $561.65 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The company had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a return on equity of 73.73% and a net margin of 20.48%. The business’s revenue was up 20.4% on a year-over-year basis. During the same period last year, the firm posted $0.10 earnings per share. As a group, sell-side analysts expect that Eli Lilly and Company will post 13.79 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.63%. The ex-dividend date of this dividend is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.